Suttle, A B
Ball, H A
Molimard, M
Hutson, T E
Carpenter, C
Rajagopalan, D
Lin, Y
Swann, S
Amado, R
Pandite, L
Article History
Received: 7 May 2014
Revised: 29 July 2014
Accepted: 18 August 2014
First Online: 28 October 2014
Change Date: 11 November 2014
Change Type: Update
Change Details: This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
Competing interests
: CC, SS, RA, and LP are employees and stockholders of GlaxoSmithKline. ABS, HAB, YL, and DR are former employees of GlaxoSmithKline and hold company stock. MM has been a consultant or advisory board consultant for AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Mundipharma, Novartis, Stallergenes, and Pfizer. TEH has been a consultant, paid researcher, and participant in advisory boards or speaker’s bureaus for Pfizer, GlaxoSmithKline, Novartis, AVEO, Johnson & Johnson, and Dendreon.